Drug Profile

Zika virus vaccine - Themis Bioscience

Alternative Names: MV-ZIKA; MV-Zika vaccine; MV-ZIKA-RSP

Latest Information Update: 28 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Themis Bioscience
Class Zika virus vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

No development reported Zika virus infection

Most Recent Events

28 Nov 2022 No recent reports of development identified for phase-I development in Zika-virus-infection(Prevention) in Austria (Parenteral)
13 Nov 2020 Zika virus vaccine is still in phase I trials for Zika virus infections in Austria (NCT04033068)
04 Nov 2020 Themis Bioscience completes a phase I trial in Zika virus infections in Austria (NCT04033068)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com